Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2Phase 3 1

Status

Recruiting 12Completed 11Active not recruiting 9Withdrawn 2Unknown 2Terminated 2Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Advanced Cancer 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × relatlimab × Clear all
NCT03724968 2021-04-20

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
2 enrolled 6 charts
Dermatologic

Melanoma

NCT02750514 2021-03-22

FRACTION-Lung

Bristol-Myers Squibb

Phase 2 Terminated
295 enrolled 21 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡